Del Cotillo Mercedes, Grané Núria, Llavoré Maria, Quintana Salvador
Hospital Mútua de Terrassa, Intensive Care Unit (ICU), Plaza Dr. Robert 5, 08221 Terrassa, Spain.
Intensive Care Med. 2008 Feb;34(2):339-43. doi: 10.1007/s00134-007-0886-6. Epub 2007 Oct 16.
The objectives were to analyze the effectiveness of heparinized solution vs. saline solution for the maintenance of arterial catheters and to detect changes in the activated partial thromboplastin time (aPTT) and platelet count in the samples extracted from both groups of arterial catheters.
Randomized, double blind, placebo-controlled clinical trial.
Intensive Care Unit of a third-level hospital in Terrassa, Barcelona, Spain.
One hundred and thirty-three patients were included in the trial. The selection criteria were: adults, informed consent, not receiving either full-dose anticoagulant or fibrinolytic treatment, and no thrombocytopenia.
Sixty-five patients received heparinized solution (1 IU/ml) and 68 received saline solution.
Arterial catheter functionality was compared in the groups every 8 h and at catheter removal. Patency, reliability of arterial pressure, and curve quality were used to evaluate the functionality of the catheters. Blood was drawn, discarding 7.5 ml, from the arterial catheter and from the venouscatheter simultaneously for coagulation tests.
The median duration of catheters being in place was 5.1 days (IQR = 8.1) in the heparin group, and 5.4 (IQR = 7.3) in the saline group (p = 0.7). Kaplan-Meier curves showed no differences between groups (p = 0.6). The number of manipulations required to maintain the patency of the arterial catheters was 35% vs. 40% (p = 0.5). The heparin group had a significantly longer aPTT (2.1 +/- .3 vs. 1.25 +/- 0.3, p = 0.001).
The use of heparinized solution for arterial catheter maintenance doesnot appear to be justified. It did not increase the duration of the catheters, nor did it improve their functionality significantly. On the other hand, heparin Na altered aPTT significantly.
分析肝素化溶液与生理盐水用于维持动脉导管的有效性,并检测从两组动脉导管抽取的样本中活化部分凝血活酶时间(aPTT)和血小板计数的变化。
随机、双盲、安慰剂对照临床试验。
西班牙巴塞罗那特拉萨一家三级医院的重症监护病房。
133名患者纳入试验。入选标准为:成年人、知情同意、未接受全剂量抗凝或纤溶治疗且无血小板减少症。
65名患者接受肝素化溶液(1 IU/ml),68名患者接受生理盐水。
每8小时及拔除导管时比较两组动脉导管功能。用通畅性、动脉压可靠性和波形质量评估导管功能。同时从动脉导管和静脉导管抽取血液,弃去7.5 ml后用于凝血试验。
肝素组导管留置中位时间为5.1天(IQR = 8.1),生理盐水组为5.4天(IQR = 7.3)(p = 0.7)。Kaplan-Meier曲线显示两组间无差异(p = 0.6)。维持动脉导管通畅所需操作次数分别为35%和40%(p = 0.5)。肝素组aPTT显著更长(2.1±0.3对1.25±0.3,p = 0.001)。
使用肝素化溶液维持动脉导管似乎没有依据。它未增加导管留置时间,也未显著改善其功能。另一方面,肝素钠显著改变了aPTT。